摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine | 749257-93-0

中文名称
——
中文别名
——
英文名称
3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine
英文别名
3-[3-(Trifluoromethyl)pyridin-2-yl]imidazo[1,2-b][1,2,4]triazine
3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine化学式
CAS
749257-93-0
化学式
C11H6F3N5
mdl
——
分子量
265.197
InChiKey
VSGASKPUORCFTE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.57±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    56
  • 氢给体数:
    0
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine硫酸硝酸 作用下, 反应 48.0h, 以84%的产率得到7-nitro-3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine
    参考文献:
    名称:
    [EN] SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN
    [FR] AMINO-HETEROCYCLES SUBSTITUES EN TANT QU'ANTAGONISTES DU VR-1 POUR TRAITER LA DOULEUR
    摘要:
    本发明提供了式I的化合物:其中:T1和T4中的一个是N,另一个是C; T2和T3独立地是N或C(CH2)nR2; X,Y和Z独立地是N或C(CH2)nR3; R1是Ar1或R1是C1-6烷基,可选地取代一个或两个Ar1基团; Ar1是可选取代的环己基,哌啶基,哌嗪基,吗啉基,金刚烷基,苯基,萘基,一个六元杂环芳香环,其中含有一个,两个或三个氮原子,一个五元杂环芳香环,其中选择了一个,两个,三个或四个杂原子从O,N和S中选择,最多只有一个O或S原子存在,或一个九元或十元的双环杂芳香环,其中苯基或上述定义的六元杂环芳香环与上述定义的六元或五元杂环芳香环融合; Ar是可选取代的苯基,一个含有一个,两个或三个氮原子的六元杂环芳香环或一个含有一个,两个,三个或四个从O,N和S中选择的杂原子的五元杂环芳香环,最多只有一个杂原子是O或S,Ar可选地取代由卤素,CF3,OCF3,C1-6烷基,C2-6烯基,C2-6炔基,硝基,氰基,异腈基,羟基,C1-6烷氧基,C1-6烷基硫基,-NR6R7,-CONR6R7,-COH,CO2H,C1-6烷氧羰基,卤代C1-6烷基,羟基C1-6烷基,氨基C1-6烷基,C1-6烷基羰基和一个含有一个,两个,三个或四个从O,N和S中选择的杂原子的五元杂环芳香环,最多只有一个杂原子是O或S,可选地被C1-6烷基,卤素,氨基,羟基或氰基取代;或其药学上可接受的盐作为VR-1配体;包含它的制药组合物;其在治疗中的用途;将其用于制造治疗疼痛的药物;以及治疗患有疼痛的受试者的方法。
    公开号:
    WO2004074290A1
  • 作为产物:
    描述:
    2-溴-1,1-二甲氧基乙烷5-[3-trifluoromethylpyridin-2-yl][1,2,4]triazin-3-amine氢溴酸 、 sodium carbonate 作用下, 以 乙醇 为溶剂, 反应 17.0h, 以31%的产率得到3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine
    参考文献:
    名称:
    [EN] SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN
    [FR] AMINO-HETEROCYCLES SUBSTITUES EN TANT QU'ANTAGONISTES DU VR-1 POUR TRAITER LA DOULEUR
    摘要:
    本发明提供了式I的化合物:其中:T1和T4中的一个是N,另一个是C; T2和T3独立地是N或C(CH2)nR2; X,Y和Z独立地是N或C(CH2)nR3; R1是Ar1或R1是C1-6烷基,可选地取代一个或两个Ar1基团; Ar1是可选取代的环己基,哌啶基,哌嗪基,吗啉基,金刚烷基,苯基,萘基,一个六元杂环芳香环,其中含有一个,两个或三个氮原子,一个五元杂环芳香环,其中选择了一个,两个,三个或四个杂原子从O,N和S中选择,最多只有一个O或S原子存在,或一个九元或十元的双环杂芳香环,其中苯基或上述定义的六元杂环芳香环与上述定义的六元或五元杂环芳香环融合; Ar是可选取代的苯基,一个含有一个,两个或三个氮原子的六元杂环芳香环或一个含有一个,两个,三个或四个从O,N和S中选择的杂原子的五元杂环芳香环,最多只有一个杂原子是O或S,Ar可选地取代由卤素,CF3,OCF3,C1-6烷基,C2-6烯基,C2-6炔基,硝基,氰基,异腈基,羟基,C1-6烷氧基,C1-6烷基硫基,-NR6R7,-CONR6R7,-COH,CO2H,C1-6烷氧羰基,卤代C1-6烷基,羟基C1-6烷基,氨基C1-6烷基,C1-6烷基羰基和一个含有一个,两个,三个或四个从O,N和S中选择的杂原子的五元杂环芳香环,最多只有一个杂原子是O或S,可选地被C1-6烷基,卤素,氨基,羟基或氰基取代;或其药学上可接受的盐作为VR-1配体;包含它的制药组合物;其在治疗中的用途;将其用于制造治疗疼痛的药物;以及治疗患有疼痛的受试者的方法。
    公开号:
    WO2004074290A1
点击查看最新优质反应信息

文献信息

  • Substituted amino heterocycles as vr-1 antagonists for treating pain
    申请人:Brown Elizabeth Rebecca
    公开号:US20060154930A1
    公开(公告)日:2006-07-13
    The present invention provides compounds of formula I: in which: one of T 1 and T 4 is N and the other is C; T 2 and T 3 are independently N or C(CH 2 ) n R 2 ; X, Y and Z are independently N or C(CH 2 ) n R 3 ; R 1 is Ar 1 or R 1 is C 1-6 alkyl optionally substituted with one or two groups Ar1; Ar1 is an optionally substituted cyclohexyl, piperidinyl, piperazinyl, morpholinyl, adamantyl, phenyl, naphthyl, a six membered heteroaromatic ring containing one, two or three nitrogen atoms, a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one O or S atom being present, or a nine- or ten-membered bicyclic heteroaromatic ring in which phenyl or a six-membered heteroaromatic ring as defined above is fused to a six- or five-membered heteroaromatic ring as defined above; Ar is an optionally substituted phenyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms or a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, Ar being optionally substituted by one, two or three groups chosen from halogen, CF 3 , OCF 3 , C 1-6 -alkyl, C 2-6 alkenyl, C 2-6 alkynyl, nitro, cyano, isonitrile, hydroxy, C 1-6 alkoxy, C 1-6 alkylthio, —NR 6 R 7 , —CONR 6 R 7 , —COH, CO 2 H, C 1-6 alkoxycarbonyl, haloC 1-4 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, C 1-4 alkylcarbonyl and a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, optionally substituted by C 1-6 alkyl, halogen, amino, hydroxy or cyano; or a pharmaceutically acceptable salt thereof as a VR-1 ligand; pharmaceutical compositions comprising it; its use in therapy; use of it in the manufacture of a medicament to treat pain; and methods of treating subjects suffering from pain.
    本发明提供了公式I的化合物:其中:T1和T4中的一个是N,另一个是C; T2和T3分别是N或C(CH2)nR2; X,Y和Z分别是N或C(CH2)nR3; R1是Ar1或R1是C1-6烷基,可选地取代一个或两个Ar1基团; Ar1是可选地取代的环己基,哌啶基,哌嗪基,吗啉基,金刚烷基,苯基,萘基,含有一个,两个或三个氮原子的六元杂环芳烃环,含有一,两,三或四个O,N和S杂原子的五元杂环芳烃环,最多只有一个O或S原子存在,或者是将苯基或上述定义的六元杂环芳烃环与上述定义的六元或五元杂环芳烃环融合而成的九元或十元双环杂环芳烃环; Ar是可选地取代的苯基,含有一个,两个或三个氮原子的六元杂环芳烃环或含有一,两个,三个或四个O,N和S杂原子的五元杂环芳烃环,最多只有一个杂原子为O或S,Ar可被一,两或三个由卤素,CF3,OCF3,C1-6烷基,C2-6烯基,C2-6炔基,硝基,氰基,异腈基,羟基,C1-6烷氧基,C1-6烷基硫基,-NR6R7,-CONR6R7,-COH,CO2H,C1-6烷氧基羰基,卤代C1-4烷基,羟基C1-6烷基,氨基C1-6烷基,C1-4烷基羰基和含有一,两个,三个或四个O,N和S杂原子的五元杂环芳烃环取代的基团取代;或其药学上可接受的盐作为VR-1配体;包含它的制药组合物;其在治疗中的应用;将其用于制造治疗疼痛的药物;以及治疗疼痛患者的方法。
  • [EN] SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN<br/>[FR] AMINO-HETEROCYCLES SUBSTITUES EN TANT QU'ANTAGONISTES DU VR-1 POUR TRAITER LA DOULEUR
    申请人:MERCK SHARP & DOHME
    公开号:WO2004074290A1
    公开(公告)日:2004-09-02
    The present invention provides compounds of formula I: in which: one of T1 and T4 is N and the other is C; T2 and T3 are independently N or C(CH2)nR2; X, Y and Z are independently N or C(CH2)nR3; R1 is Ar1 or R1 is C1-6alkyl optionally substituted with one or two groups Ar1; Ar1 is an optionally substituted cyclohexyl, piperidinyl, piperazinyl, morpholinyl, adamantyl, phenyl, naphthyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms, a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one O or S atom being present, or a nine- or ten-membered bicyclic heteroaromatic ring in which phenyl or a six-membered heteroaromatic ring as defined above is fused to a six-or five-membered heteroaromatic ring as defined above; Ar is an optionally substituted phenyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms or a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, Ar being optionally substituted by one, two or three groups chosen from halogen, CF3, OCF3, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, nitro, cyano, isonitrile, hydroxy, C1-6alkoxy, C1-6alkylthio, -NR6R7, -CONR6R7, -COH, CO2H, C1-6alkoxycarbonyl, haloC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, C1-6alkylcarbonyl and a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, optionally substituted by C1-6alkyl, halogen, amino, hydroxy or cyano; or a pharmaceutically acceptable salt thereof as a VR-1 ligand; pharmaceutical compositions comprising it; its use in therapy; use of it in the manufacture of a medicament to treat pain; and methods of treating subjects suffering from pain.
    本发明提供了式I的化合物:其中:T1和T4中的一个是N,另一个是C; T2和T3独立地是N或C(CH2)nR2; X,Y和Z独立地是N或C(CH2)nR3; R1是Ar1或R1是C1-6烷基,可选地取代一个或两个Ar1基团; Ar1是可选取代的环己基,哌啶基,哌嗪基,吗啉基,金刚烷基,苯基,萘基,一个六元杂环芳香环,其中含有一个,两个或三个氮原子,一个五元杂环芳香环,其中选择了一个,两个,三个或四个杂原子从O,N和S中选择,最多只有一个O或S原子存在,或一个九元或十元的双环杂芳香环,其中苯基或上述定义的六元杂环芳香环与上述定义的六元或五元杂环芳香环融合; Ar是可选取代的苯基,一个含有一个,两个或三个氮原子的六元杂环芳香环或一个含有一个,两个,三个或四个从O,N和S中选择的杂原子的五元杂环芳香环,最多只有一个杂原子是O或S,Ar可选地取代由卤素,CF3,OCF3,C1-6烷基,C2-6烯基,C2-6炔基,硝基,氰基,异腈基,羟基,C1-6烷氧基,C1-6烷基硫基,-NR6R7,-CONR6R7,-COH,CO2H,C1-6烷氧羰基,卤代C1-6烷基,羟基C1-6烷基,氨基C1-6烷基,C1-6烷基羰基和一个含有一个,两个,三个或四个从O,N和S中选择的杂原子的五元杂环芳香环,最多只有一个杂原子是O或S,可选地被C1-6烷基,卤素,氨基,羟基或氰基取代;或其药学上可接受的盐作为VR-1配体;包含它的制药组合物;其在治疗中的用途;将其用于制造治疗疼痛的药物;以及治疗患有疼痛的受试者的方法。
查看更多

同类化合物

咪唑并[1,2-b][1,2,4]三唑并[4,3-D][1,2,4]三嗪 3-甲基咪唑并[1,2-b][1,2,4]噻嗪 3-溴-7-甲基咪唑并[1,2-b][1,2,4]三嗪 3-(三氟甲基)咪唑并[1,2-b][1,2,4]三嗪 2-咪唑并[1,2-B][1,2,4]三嗪-7-丙烷-2-醇 2-(3-溴咪唑并[1,2-b][1,2,4]-7-三嗪)丙烷-2-醇 3-(3-methylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine 2-imidazo[1,2-b][1,2,4]triazin-3-ylpropan-2-ol hydrochloride 2,2'-(7,7'-biimidazo[1,2-b][1,2,4]triazine-3,3'-diyl)dipropan-2-ol 2-(2,4-difluorophenyl)-6-((pyridin-2-yloxy)methyl)imidazo[1,2-b][1,2,4]triazine 2-(4-fluorophenyl)-7-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,2-b]-[1,2,4]-triazine 7-Bromo-2-methylimidazo[1,2-b][1,2,4]triazine 1,2,3,4-tetrahydro-dibenzo[4,5:e]imidazo[1,2-b][1,2,4]triazine 2-(7-bromo-imidazo[1,2-b][1,2,4]triazin-3-yl)-propan-2-ol imidazo[1,2-b][1,2,4]triazine-6-carboxylic acid ethyl ester 2-(imidazo[1,2-b][1,2,4]triazin-6-yl)ethanol 2-(4-fluorophenyl)-7-(4-methoxybenzyl)imidazo[1,2-b][1,2,4]triazine 7,9-Dimethylimidazo[1,2-b][1,2,4]benzotriazine 7-Methylimidazo[1,2-b][1,2,4]benzotriazine 7-Methoxyimidazo[1,2-b][1,2,4]benzotriazine imidazo[1,2-b][1,2,4]triazine-6-carbaldehyde 3-[3-trifluoromethylpyridin-2-yl]imidazo[1,2-b][1,2,4]triazin-7-amine 7-nitro-3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine Imidazo[1,2-b][1,2,4]triazin-2(1H)-one 6-(3-Methoxycyclohexyl)-2-phenylimidazo[1,2-b][1,2,4]triazine 3-(3-trifluoromethylpyridin-2-yl)imidazo[1,2-b][1,2,4]triazine 2,3-diphenyl-6-thiophen-2-yl-imidazo[1,2-b][1,2,4]triazine 7-(2-chloropyridin-4-yl)-3-trifluoromethylimidazo[1,2-b][1,2,4]triazine 3-(1-fluoro-1-methylethyl)imidazo[1,2-b][1,2,4]triazine 7-[(3,4-dihydroxyphenyl)methylidene]-3-methyl-2-methylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one 6-(5-Chlorothiophen-2-yl)-2,3-dimethylimidazo[1,2-b][1,2,4]triazine 6-(5-Bromothiophen-2-yl)-2,3-dipyridin-2-ylimidazo[1,2-b][1,2,4]triazine 7-[(3,4-dihydroxyphenyl)methylidene]-3-ethyl-2-ethylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one 2-(5-{7-[2-(difluoromethoxy)benzyl]-6-methylimidazo[1,2-b][1,2,4]triazin-2-yl}-pyrimidin-2-yl)propan-2-ol 2-[2-Chloro-4-[2-[2-cyclopentyl-5-(imidazo[1,2-b][1,2,4]triazin-6-ylmethyl)-4,6-dioxooxan-2-yl]ethyl]phenyl]-2-methylpropanenitrile (7E)-3-methyl-2-methylidene-7-[(2,3,4-trimethoxyphenyl)methylidene]-1H-imidazo[1,2-b][1,2,4]triazin-6-one (3E)-3-[(2-chloro-6-fluorophenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (3Z)-3-[(3-methoxyphenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12Z)-12-[(2,4-dichlorophenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (12E)-12-[(4-chlorophenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (3E)-3-(thiophen-2-ylmethylidene)-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12E)-12-[[4-(dimethylamino)phenyl]methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (7E)-7-[(2-methoxyphenyl)methylidene]-3-methyl-2-methylidene-1H-imidazo[1,2-b][1,2,4]triazin-6-one (3E)-3-[(3,4-dihydroxyphenyl)methylidene]-1,6,7,8-tetrahydroimidazo[1,2-b][1,2,4]benzotriazin-2-one (12E)-12-[(3,4,5-trimethoxyphenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one (12E)-12-[(2-methoxyphenyl)methylidene]-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,6,8-trien-11-one 2-(Azepan-1-yl)-3-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-b][1,2,4]triazine 4-[(11-Hydroxy-1,2,8,10-tetrazatricyclo[7.3.0.03,7]dodeca-2,7,9,11-tetraen-12-yl)methylidene]-2-methoxycyclohexa-2,5-dien-1-one 2-(1-Adamantyl)-6,7,8,9-tetrahydroimidazo[1,2-b][1,2,4]benzotriazine 6-[1-(Furan-2-ylmethyl)-2,5-dimethylpyrrol-3-yl]-2,3-diphenylimidazo[1,2-b][1,2,4]triazine